OPEN APP
Home / Science / Health /  Covid-19: Optimus concludes Phase 3 clinical trial of Molnupiravir oral capsule
Listen to this article

Optimus Pharma has announced that it has successfully completed Phase 3 clinical trial of Molnupiravir oral capsule. It is an experimental drug used for treating Covid-19 patients.

On May 18, 2021, the Hyderabad-based bulk drugs manufacturer had received approval from the Drugs Controller General of India (DCGI) to conduct the trial as per the recommendations of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO), under Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare.

As per the study on day five, 78.4 per cent of the patients in the treatment group were recorded RT-PCR negative as compared to 48.2 per cent in the placebo group.

Similarly, on the 10th day, 91.5 per cent of the patients in the treatment group were recorded RT-PCR negative as compared to 43 per cent in the placebo group.

"Our aim is to develop a cutting-edge and affordable treatment option for COVID-19 and neutralise the disease in minimum treatment duration. We are fully committed to supporting our business partners across various regions of the world who are counting on us for the supply of Molnupiravir," Optimus Pharma Chairman and Managing Director D Srinivas Reddy stated.

Optimus was the first drug firm to file for Phase 3 clinical trial of Molnupiravir with the central licensing authority.

The study was conducting across 29 sites, roughly covering 96 per cent of the nation's demography.

Established in 2004 as custom synthesis laboratory by a team of techno-commercial experts, Optimus is now one of the fastest growing manufacturers of active pharmaceutical ingredients (APIs) and finished dosages.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Close
Recommended For You
×
Edit Profile
Get alerts on WhatsApp
Set Preferences My ReadsFeedbackRedeem a Gift CardLogout